title: Studies on porcine circovirus type 2 vaccination of 5-day-old piglets.
abstract: Porcine circovirus type 2 (PCV2) vaccines have become widely used since they became available in 2006. It is not uncommon for producers to use PCV2 vaccines in pigs younger than what is approved by manufacturers. The objective of this study was to determine the efficacy of a chimeric and a subunit PCV2 vaccine administered at 5 or 21 days of age. Forty-eight PCV2-naïve piglets were randomly divided into six groups of eight pigs each. Vaccination was done at day 5 or day 21, followed by triple challenge with PCV2, porcine parvovirus (PPV), and porcine reproductive and respiratory syndrome virus (PRRSV) at day 49. Vaccinated pigs seroconverted to PCV2 approximately 14 days postvaccination and had a detectable neutralizing antibody response by 21 days postvaccination regardless of age at vaccination. At day 49, the pigs vaccinated with the chimeric vaccine had significantly higher levels of neutralizing antibodies than the pigs vaccinated with the subunit vaccine. After challenge, vaccinated pigs had significantly decreased levels of PCV2 viremia and a decreased prevalence and severity of microscopic lesions compared to the positive-control group, which had severe lymphoid lesions associated with abundant PCV2 antigen, compatible with PCV-associated disease. The results of this study indicate that, under the conditions of this study, vaccination of PCV2-naïve pigs at day 5 or day 21 resulted in development of a detectable humoral immune response and provided reduction or complete protection against PCV2 viremia and PCV2-associated lesions after triple challenge with PCV2, PPV, and PRRSV.
authors.affiliation: Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, 1600 S. 16th Street, Ames, IA 50011, USA.
authors.forename: K C
authors.initials: KC
authors.lastname: O'Neill
authors.forename: H G
authors.initials: HG
authors.lastname: Shen
authors.forename: K
authors.initials: K
authors.lastname: Lin
authors.forename: M
authors.initials: M
authors.lastname: Hemann
authors.forename: N M
authors.initials: NM
authors.lastname: Beach
authors.forename: X J
authors.initials: XJ
authors.lastname: Meng
authors.forename: P G
authors.initials: PG
authors.lastname: Halbur
authors.forename: T
authors.initials: T
authors.lastname: Opriessnig
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D057134:Antibodies, Neutralizing / Q000097:blood; D000914:Antibodies, Viral / Q000097:blood; D017925:Circovirus / Q000276:immunology*; D053570:Porcine Postweaning Multisystemic Wasting Syndrome / Q000276:immunology / Q000517:prevention & control*; D013552:Swine; D013997:Time Factors; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014765:Viral Vaccines